Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

PHASE2CompletedINTERVENTIONAL
Enrollment

369

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Anxiety Disorders
Interventions
DRUG

AZD7325

4 tablets and 1 capsule taken twice a day for 28 days

DRUG

AZD7325

4 tablets and 1 capsule taken twice a day for 28 days

DRUG

Lorazepam

4 tablets and 1 capsule taken twice a day for 28 days

DRUG

Placebo

4 tablets and 1 capsule taken twice a day for 28 days

Trial Locations (51)

Unknown

Research Site, Mesa

Research Site, Little Rock

Research Site, Carson

Research Site, Escondido

Research Site, Glendale

Research Site, Irvine

Research Site, Redlands

Research Site, Riverside

Research Site, Sherman Oaks

Research Site, Fort Lauderdale

Research Site, Fort Myers

Research Site, Gainsville

Research Site, Hallandale

Research Site, Jacksonville

Research Site, Maitland

Research Site, Orlando

Research Site, St. Petersburg

Research Site, Tampa

Research Site, West Palm Beach

Research Site, Atlanta

Research Site, Hoffman Estates

Research Site, Oak Brook

Research Site, Schaumburg

Research Site, Lafayette

Research Site, Terre Haute

Research Site, Shreveport

Research Site, Glen Burnie

Research Site, Westminster

Research Site, Braintree

Research Site, Piscataway

Research Site, Cedarhurst

Research Site, New York

Research Site, Staten Island

Research Site, Raleigh

Research Site, Cincinnati

Research Site, Cleveland

Research Site, Dayton

Research Site, Willoughby

Research Site, Oklahoma City

Research Site, Eugene

Research Site, Salem

Research Site, Allentown

Research Site, Philadelphia

Research Site, Charleston

Research Site, Bartlett

Research Site, Austin

Research Site, Dallas

Research Site, San Antonio

Research Site, Wichita Falls

Research Site, Richmond

Research Site, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY